- Conditions
- Memory Impairment Due to Corticosteroid Use, Hypomania Due to Corticosteroid Use, Hippocampal Atrophy Due to Corticosteroid
- Interventions
- Lamotrigine (Drug)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 691
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Allergic Asthma
- Interventions
- Placebo, Omalizumab, Immunotherapy
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Migraine
- Interventions
- metoclopramide, Dexamethasone, methylprednisolone acetate
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- The Bronx, New York
- Conditions
- Diabetic Macular Edema
- Interventions
- intravitreal ranibizumab 0.3 mg, dexamethasone intravitreal implant, Sham injection
- Drug · Procedure
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 56
- States / cities
- Beverly Hills, California • Huntington Beach, California • Loma Linda, California + 47 more
- Conditions
- Graft vs Host Disease, Immune System Disorders
- Interventions
- Etanercept, Mycophenolate Mofetil, Denileukin Diftitox, Pentostatin
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 19
- States / cities
- Duarte, California • San Diego, California • Stanford, California + 16 more
- Conditions
- Graft-Versus-Host Disease
- Interventions
- MSC
- Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 4 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD)
- Interventions
- Betamethasone
- Drug
- Lead sponsor
- Khang Nguyen
- Other
- Eligibility
- Up to 28 Weeks
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Asthma
- Interventions
- QBX258, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 15
- States / cities
- Anaheim, California • Riverside, California • Rolling Hills Estates, California + 11 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- Bone Marrow Derived MSCs, Corticosteroid, Bone Marrow Aspirate
- Biological · Drug · Device
- Lead sponsor
- Next Generation Regenerative Medicine LLC
- Network
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Chesterfield, Missouri • Steubenville, Ohio • Salt Lake City, Utah
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anifrolumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Herpes Simplex Virus Keratitis
- Interventions
- oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypereosinophilia, Hypereosinophilic Syndrome
- Interventions
- mepolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 11
- States / cities
- San Diego, California • Denver, Colorado • Bethesda, Maryland + 8 more
- Conditions
- Ulcerative Colitis
- Interventions
- Mesalazine, IV Corticosteroid, Oral Corticosteroids, Additional Therapies, Colectomy
- Drug · Other · Procedure
- Lead sponsor
- Connecticut Children's Medical Center
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 26
- States / cities
- Los Angeles, California • San Francisco, California • Hartford, Connecticut + 22 more
- Conditions
- Physiological Effects of Drugs
- Interventions
- Memantine
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Asthma, Pediatric ALL
- Interventions
- budesonide, beclomethasone
- Drug
- Lead sponsor
- New York City Health and Hospitals Corporation
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix, Distal Urethral Cancer, Fallopian Tube Cancer, Gastrinoma, Glucagonoma, Inflammatory Breast Cancer, Insulinoma, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Lung Metastases, Male Breast Cancer, Malignant Pericardial Effusion, Malignant Pleural Effusion, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Parathyroid Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Newly Diagnosed Carcinoma of Unknown Primary, Occult Non-small Cell Lung Cancer, Pancreatic Polypeptide Tumor, Primary Peritoneal Cavity Cancer, Proximal Urethral Cancer, Pulmonary Carcinoid Tumor, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adrenocortical Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Carcinoma of Unknown Primary, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Endometrial Carcinoma, Recurrent Esophageal Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Parathyroid Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Thyroid Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Skin Metastases, Small Intestine Adenocarcinoma, Somatostatinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Adrenocortical Carcinoma, Stage III Bladder Cancer, Stage III Cervical Cancer, Stage III Colon Cancer, Stage III Endometrial Carcinoma, Stage III Esophageal Cancer, Stage III Follicular Thyroid Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Ovarian Epithelial Cancer, Stage III Pancreatic Cancer, Stage III Papillary Thyroid Cancer, Stage III Prostate Cancer, Stage III Rectal Cancer, Stage III Renal Cell Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Anal Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Anal Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Adrenocortical Carcinoma, Stage IV Anal Cancer, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Endometrial Carcinoma, Stage IV Esophageal Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Gastric Cancer, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Papillary Thyroid Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Urethral Cancer Associated With Invasive Bladder Cancer, WDHA Syndrome
- Interventions
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Asthma
- Interventions
- Placebo, Fluticasone propionate, BI 54903
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 37
- States / cities
- Fountain Valley, California • Fullerton, California • Long Beach, California + 33 more
- Conditions
- Asthma
- Interventions
- Automated Phone-Based Refill Reminders
- Behavioral
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14,064 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Honolulu, Hawaii • Portland, Oregon
- Conditions
- Asthma
- Interventions
- dupilumab, Matching Placebo, ICS/LABA
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 51
- States / cities
- Bakersfield, California • La Jolla, California • Lancaster, California + 47 more
- Conditions
- Cystoid Macular Edema, Uveitis
- Interventions
- Vitamin E
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Post-traumatic Stress Disorder
- Interventions
- prednisone, placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium and Olodaterol (Tio+Olo), Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 27,190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Lateral Epicondylitis
- Interventions
- Prolotherapy, Local Corticosteroid Therapy
- Drug
- Lead sponsor
- Spaulding Rehabilitation Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Wellesley, Massachusetts